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ABSTRACT
Introduction: Cervical radiculopathy due to discogenic
or spondylotic stenosis of the neuroforamen can be
surgically treated by an anterior discectomy with fusion
(ACDF) or a posterior foraminotomy (FOR). Most
surgeons prefer ACDF, although there are indications
that FOR is as effective as ACDF, has a lower
complication rate and is less expensive. A head-to-
head comparison of the 2 surgical techniques in a
randomised controlled trial has not yet been
performed. The study objectives of the Foraminotomy
ACDF Cost-Effectiveness Trial (FACET) study are to
compare clinical outcomes, complication rates and
cost-effectiveness of FOR to ACDF.
Methods and analysis: The FACET study is a
prospective randomised controlled trial conducted in 7
medical centres in the Netherlands. The follow-up
period is 2 years. The main inclusion criterion is a
radiculopathy of the C4, C5, C6 or C7 nerve root, due
to a single-level isolated cervical foraminal stenosis
caused by a soft disc and/or osteophytic component,
requiring operative decompression. A sample size of
308 patients is required to test the hypothesis of
clinical non-inferiority of FOR versus ACDF. Primary
outcomes are: ‘operative success’, the measured
decrease in radiculopathy assessed by the visual
analogue scale and ‘patient success’, assessed by the
modified Odom’s criteria. Secondary outcomes are:
Work Ability Index (single-item WAI), quality of life
(EuroQol 5 Dimensions 5 level Survey, EQ-5D-5L),
Neck Disability Index (NDI) and complications. An
economic evaluation will assess cost-effectiveness. In
addition, a budget impact analysis will be performed.
Ethics and dissemination: Ethical approval was
obtained from the Institutional Ethics Committee of the
University Medical Center Groningen. Results of this
study will be disseminated through national and
international papers. The participants and relevant
patient support groups will be informed about the
results of the study.
Trial registration number: NTR5536, pre-results.
INTRODUCTION
Background and rationale
Cervical radiculopathy has a serious impact
on a patient’s quality of life (QoL). Many
patients with a cervical radiculopathy are in
their productive phase of life and are part of
their community’s labour force. Therefore,
temporary disability due to the radiculopathy
may result in a major loss of productivity.
A cervical radicular syndrome (CRS) con-
stitutes pain, paresis and/or paraesthesia in
the distribution area of the corresponding
nerve root. It can be caused by nerve root
compression due to soft disc protrusion or
by a spondylotic stenosis of the neurofora-
men. The annual incidence of a CRS is
Strengths and limitations of this study
▪ The Foraminotomy ACDF Cost-Effectiveness Trial
(FACET) study is the first randomised controlled
trial investigating anterior discectomy with fusion
versus foraminotomy for cervical foraminal
pathology.
▪ Methodological strengths include an appropriate
sample size based on a non-inferiority design,
seven participating medical centres and an inde-
pendent institute facilitating the randomisation
system and monitoring activities.
▪ The study is performed with care as usual; there-
fore, the final results of this study could be gen-
eralisable to usual clinical practice.
▪ With respect to the evaluation of spinal fusion
and instrumentation failure, the relatively short
follow-up period of 2 years could be a limitation
of this study.
▪ In this study, it is not feasible to blind the par-
ticipant and the surgeon to the allocated
treatment.
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estimated at 0.8 per 1000 inhabitants.1 The initial treat-
ment is primarily conservative. The revised Dutch CRS
guideline (2010) states that a CRS existing for longer
than 2 months, and not responding to conservative treat-
ment in that time course, can be considered an indica-
tion for surgical treatment.2
Various surgical approaches for the treatment of cer-
vical radiculopathy have been described. Spurling and
Scoville3 reported the successful removal of the cervical
disc with a hemilaminectomy in 1944. In the following
years, the techniques further evolved into a keyhole fora-
minotomy (FOR) being popularised by Frykholm.4
Cloward,5 Smith and Robinson6 developed the anterior
approach for cervical discectomy in 1958. Since then,
anterior cervical discectomy with fusion (ACDF) has
become very popular and became the favourite treat-
ment option in the majority of neurosurgeons and
orthopaedic surgeons for cervical degenerative disc dis-
eases with stenosis of the central spinal canal.7 8
For lateral pathologies, such as the foraminal soft disc
protrusion or spondylotic stenosis of the neuroforamen,
there is still a controversy regarding the best surgical
approach. Both the anterior and posterior techniques
are well established, but the decision to choose one tech-
nique above the other is often based on the surgeon’s
preference and not on scientiﬁc evidence.9–11
The majority of surgeons seem to favour the anterior
approach. This preference is probably based on the fact
that the anterior approach is also used for other cervical
disorders, causing the surgeon to be more familiar with
this operative route. Furthermore, the assumption that
the posterior approach elicits more postoperative neck
pain makes this technique less appealing for surgeons.12
However, there are also several advantages of the pos-
terior approach in patients with a foraminal soft disc
protrusion or spondylotic stenosis.
Four of these advantages are:
1. Clinical outcome after a posterior cervical FOR
appears non-inferior to ACDF. There are conﬂicting
results, derived from low-quality, mainly retrospective
studies.9–11 13 In a large study of Dohrmann and
Hsieh,14 6000 patients were analysed retrospectively
from the existing literature. A good/excellent result
(relief of symptoms) was scored in 80% of the
patients after an anterior decompression versus 94%
of the patients after a posterior decompression. This
difference was statistically signiﬁcant (p<0.05).14 On
the other hand, Korinth et al11 found, in a retrospect-
ive study of 292 patients, a statistically signiﬁcant dif-
ference in success rate (Odom’s criteria I and II) in
favour of ACDF with polymethylmethacrylate (PMMA)
stabilisation compared with FOR. Furthermore, Wirth
and colleagues conducted a prospective trial compar-
ing (1) anterior cervical discectomy without fusion
(ACD), (2) ACDF and (3) FOR. The study did not
show a signiﬁcant difference in outcome between the
three procedures (pain improvement in 100% of the
patients after ACDF or FOR, 92% after ACD).
However, the number of patients included in the
study was very low (n=72).10
2. Morbidity data are in favour of FOR. The lower com-
plication rate for FOR can be explained by the differ-
ence in anatomical structures that are involved in the
two approaches. Owing to the proximity of vulner-
able and vital structures such as the carotid artery,
vagal nerve, trachea, oesophagus and the recurrent
laryngeal nerve, ACDF has a higher complication
rate. The reported numbers of complications in the
literature vary between 6.5% and 19.3% for the ACDF
technique, and between 1.8% and 3.9% in the case of
FOR.13 15–19
3. Direct costs of FOR seem to be lower. The explan-
ation for this is most likely the high costs of implants
used in ACDF. Mansﬁeld et al18 reported an average
difference of $3872 between ACDF and FOR, with
$3143 of this difference contributable to costs in the
operating room (including materials). Tumialán
et al20 found a difference of $6508 between FOR and
ACDF with plating. Approximately half of these extra
costs were caused by the implants used.
4. Indirect costs of FOR seem lower, which may be
related to a faster rehabilitation and an earlier
resumption of work. However, this assumption is
based on two retrospective studies comparing the
cost-effectiveness of FOR to ACDF with plating. A
comparison to ACDF without plating has not yet
been made.20 21
In summary, a high-quality study comparing the effect-
iveness of FOR to ACDF has not yet been performed.
Patients, the medical community and ﬁnancial stake-
holders would beneﬁt from a study that puts both proce-
dures to the test. The results of this study could be of
use for the update/revision of the (inter)national guide-
lines for the treatment of a CRS.
Aims and hypotheses
The Foraminotomy ACDF Cost-Effectiveness Trial
(FACET) study is designed as a high-quality study to
analyse the cost-effectiveness of the FOR technique com-
pared with ACDF in patients with a cervical monoradicu-
lopathy caused by a discogenic and/or osteophytic
foraminal stenosis.
The primary hypotheses are:
▸ The effectiveness of the FOR technique is non-
inferior compared with the ACDF technique.
▸ The FOR technique is cost-effective compared with
the ACDF technique.
The secondary hypotheses are:
▸ The FOR technique will have a lower complication
rate compared with the ACDF technique.
▸ The FOR technique will have lower direct and indir-
ect costs compared with the ACDF technique.
▸ The FOR technique is associated with more neck
pain in the ﬁrst 30 days after the surgical procedure.
2 Broekema AEH, et al. BMJ Open 2017;7:e012829. doi:10.1136/bmjopen-2016-012829
Open Access
group.bmj.com on November 20, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
Trial design
The FACET study is a nationwide, prospective, multicen-
tre, investigator-blinded randomised controlled trial with
a follow-up of 2 years. A total of 308 participants will be
included in seven medical centres in the Netherlands
during 2 years. Both the FOR (experimental group) and
the ACDF (active control) are established surgical tech-
niques. A non-inferiority trial design was chosen to show
whether FOR has at least as much efﬁcacy as the ACDF
technique or is worse by an amount <10% with regard
to the primary outcome parameters.
METHODS AND ANALYSIS
Study setting
The study will focus on patients with a monosegmental
radicular syndrome due to a lateral or foraminal her-
niated disc or osteophyte, with compression of the C4,
C5, C6 or C7 nerve root. Patients will be informed about
the study at the outpatient clinics of the participating
hospitals. Participating neurosurgeons are from the
University Medical Center Groningen, Martini Hospital
Groningen, Radboud University Medical Center
Nijmegen, Canisius Wilhelmina Hospital Nijmegen,
Zuyderland Medical Center Heerlen, Medical Center
Haaglanden and Medisch Spectrum Twente Enschede.
Two centres are university teaching hospitals, and ﬁve
are large regional medical centres. The participating
hospitals were selected because of the high volume of
spinal cases and their neurosurgeons’ familiarity with
the two procedures under investigation. The participat-
ing centres are evenly distributed over the Netherlands,
which will result in a study population that reﬂects the
population of the entire country.
Patient inclusion criteria
In order to be eligible to participate in this study, a par-
ticipant must meet all of the following criteria:
▸ Age between 18 and 80 years.
▸ Single-level isolated cervical foraminal stenosis due to
a soft disc or osteophytic component causing radicu-
lopathy of C4, C5, C6 or C7 and requiring decom-
pression of neuroforamen. (Foraminal stenosis due to
a soft disc component is deﬁned as: 2/3 of the total
discal component is located intraforaminally and a
maximum of 1/3 of the total discogenic component
is located medially within the spinal canal.
Radiculopathy is deﬁned as pain, paresis and/or par-
aesthesia in corresponding nerve root distribution
areas of C4, C5, C6 or C7, and must include at least
arm or shoulder pain with a minimum of 30 mm on
a 100 mm visual analogue scale (VAS).)
▸ Failure to respond to conservative treatment for
8 weeks or, during these 8 weeks, progressive signs or
symptoms of nerve root compression.
▸ Discogenic or spondylotic foraminal stenosis (deter-
mined by MRI or CT, with or without an oblique
X-ray of the cervical spine) at the anatomical level
that correlates with the clinical symptoms.
▸ Psychologically and physically able to comply with the
study-related procedures.
▸ Sufﬁcient mastery of the Dutch language to ﬁll out
the questionnaires.
▸ Signed and dated informed consent form, prior to
any study-related procedures.
Patient exclusion criteria
A potential participant who meets any of the following
criteria will be excluded from participation in this study:
▸ Multisegmental CRS.
▸ Median located disc protrusion or osteophytic protru-
sion (median located protrusion is deﬁned as >1/3 of
the total discogenic component is located medially
within the spinal canal).
▸ C8 radiculopathy.
▸ Spinal cord compression with clinical myelopathy.
▸ Pure axial neck pain without radicular pain.
▸ Radiological signs of cervical myelopathy.
▸ History of cervical spine surgery.
▸ Morbid obesity (body mass index >30).
▸ Osteoporosis or chronic use of corticosteroids.
▸ American Society of Anesthesiologists Physical Status
Classiﬁcation System (ASA) 4 and 5 patients (seriously
ill patients).
▸ Pregnancy.
▸ Active malignancy.
▸ Abundant use of alcohol, drugs or narcotics.
▸ Contraindications for anaesthesia or surgery.
▸ The participant has used another investigational drug
or device within the 30 days prior to surgery.
▸ Incapability to speak and write the Dutch language
Investigational treatment
ACDF technique:
Microsurgical discectomy is performed by a ventral
approach described by Smith and Robinson.6 The pro-
cedure can be executed with microscope or loupe mag-
niﬁcation. The content of the intervertebral disc is
exposed and removed. The posterior ligament is incised
and removed with rongeurs. Disc fragments that are
extruded into the neuroforamen are removed. If an
osteophytic component is present, this part of the unco-
vertebral joint is reduced. An intervertebral spacer (cage
or PMMA) is inserted into the intervertebral disc space.
No additional plate ﬁxation is used.
FOR technique:
All patients are operated in the prone position with
the head in a three-point head holder. After ﬂuoroscopy
to determine the correct level, a vertical midline incision
is made, and the ipsilateral lamina and facet joints are
exposed. After a second conﬁrmation of the correct
level, a partial hemilaminectomy and FOR of the
involved level is performed with the use of an operating
microscope or loupe magniﬁcation. The amount of
reduction of the facet joint is determined by the extent
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of the foraminal stenosis. In cases of soft disc compres-
sions, the proximal root is visualised adequately and
mobilised to allow the removal of the compressing disc
material. However, complete removal of the soft disc
component is not strictly necessary and the decision to
remove the soft component will be left to the surgeon’s
preference. In cases of an osteophytic foraminal stenosis,
bony decompression of the proximal root is performed.
The surgeon has the choice to carefully coagulate and
divide the venous plexus that covers the nerve sheath.
Main study parameters
The primary study parameters are ‘operative success’
and ‘patient success’.
‘Operative success’ will be the postoperative decrease
in radiculopathy assessed by the VAS for self-reported
arm pain, between the patients operated with the FOR
technique and with the ACDF technique during
24 months of follow-up. We will consider the decrease in
radiculopathy clinically relevant when the postoperative
decrease is more than 41 mm on the VAS for arm
pain.22
‘Patient success’ will be assessed by the modiﬁed
Odom’s criteria, which address physical symptoms and
socioeconomic status. We will consider the ﬁrst and
second categories (‘excellent’ and ‘good’) as a success-
ful outcome of the operation.
The distinction between ‘patient success’ and ‘opera-
tive success’ is made because a patient could have full
improvement of the radiculopathy causing arm pain, but
would not be satisﬁed with the operation because he or
she is not able to perform his or her daily activities, for
example, because of a persistent sensibility disorder in
the ﬁngertips.23–25
Secondary study parameters are:
1. Differences in postoperative work ability during
24 months of follow-up.26
2. Differences in postoperative QoL during 24 months
of follow-up.27
3. Changes and differences in neck pain in the short
term after the procedure (weekly assessed in the ﬁrst
6 weeks postoperative) and during the 24 months of
follow-up.23
4. Differences in neck disability during 24 months of
follow-up.28
5. Type of complications and complication rates in the
short-term (30 days) and long-term (24 months)
periods.
6. Cost-effectiveness (24 months).
7. Budget impact (extrapolated to 5 years).
Participant timeline
The inclusion of participants has started on 1 December
2015. The total follow-up is 2 years. At baseline (ie, at
enrolment, before the surgical procedure) and at 6, 26,
52, 78 and 104 weeks after the surgical procedure, parti-
cipants will ﬁll out web-based questionnaires. These
questionnaires take ∼30 min to ﬁll in. A short
questionnaire, addressing only the arm and neck pain
(VAS), will be used weekly from the surgical intervention
until the visit to the outpatient clinic after 6 weeks.
The participant will visit the outpatient clinic 6 weeks
after the surgical procedure, in line with standard care.
An independent interviewer will contact the participants
by telephone at 26, 52, 78 and 104 weeks to assess
Odom’s criteria. For a schematic diagram, see table 1.
Sample size calculation
The sample size analysis is based on the manuscript of
Dohrmann and Hsieh.14 Based on this review of cohort
studies, an overall success rate of 87% for both groups
was detected. Based on the current guidelines of the
CRS, there is evidence that FOR is not worse in compari-
son with ACDF concerning decrease in arm pain.2
Therefore, the assumption is that there will not be a stat-
istically signiﬁcant difference between the two surgical
techniques concerning the primary outcome measure
(relief of arm pain). With the aforementioned success
rate in mind, an α of 0.05, power of 0.8 and a non-
inferiority margin (δ) of 10%, the authors conducted a
sample size calculation. Including 10% drop outs, a total
sample size of 308 participants was calculated, which
means 154 participants per treatment arm.
Recruitment
Enrolment will take place at the outpatient clinics of the
participating medical centres. When a patient with a
CRS is indicated for a surgical treatment, the attending
neurosurgeon judges if the patient is eligible for the
trial. If the patient fulﬁls the inclusion and exclusion cri-
teria, he or she is informed about the possibility to par-
ticipate in the study.
To determine if the inclusion rate of 308 participants
is feasible, we asked 25 patients (with a cervical radiculo-
pathy due to a foraminal compression) in one of the
outpatient clinics whether they would participate in a
surgical randomised controlled trial. More than 80% of
the patients were willing to participate. Furthermore, it
was calculated that with a low inclusion rate of 30% each
year, the authors will be able to include 308 participants
in 2 years. For 7 participating centres, this implies an
inclusion rate of ∼2 participants per centre per month.
Randomisation and treatment allocation
Participants are randomised to either FOR or ACDF.
Randomisation will be executed per participant per
centre, by web-based block randomisation after the
informed consent procedure is fulﬁlled. An independ-
ent institute, the Trial Coordination Center of the
University Medical Center Groningen, will facilitate the
randomisation.
Blinding
In this trial, blinding of the participant or the surgeon is
not feasible. The data analysis will be performed with
blinded data. Assessment of Odom’s criteria will be
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performed by an independent interviewer who is
blinded to the treatment allocation.
Data collection methods
Preoperative history is obtained from standard care pro-
cedures and includes length, weight, number of
months/years of neck and arm pain, signs and symp-
toms, other signiﬁcant illnesses, pain medication (use of
non-steroidal anti-inﬂammatory drugs) and smoking
history. Information about the operative procedure will
be obtained from the medical record of the participant
and will include date and type of procedure, which level
was operated, use of implants and the occurrence of
complications during the operative procedure.
At baseline, discharge and 6 weeks after the proced-
ure, a clinical evaluation will be performed. Information
will be recorded on signs and symptoms, reﬂexes, sens-
ibility and strength.
Outcome measurements
Primary outcomes:
‘Operative success’ will be the postoperative decrease
in radiculopathy assessed by the VAS for self-reported
arm pain, between the patients operated with the FOR
technique and with the ACDF technique during
24 months of follow-up. The VAS is a well-known and
validated outcome measurement.23 It is provided to the
participants as a horizontal scale ranging from 0 to
100 mm.
‘Patient success’ will be assessed by the modiﬁed
Odom’s criteria, which address physical symptoms and
socioeconomic status. Odom’s criteria have been widely
used in studies regarding different cervical procedures
and assess the improvement of the physical symptoms
and the ability to perform daily activities.24 Although
Odom’s criteria have not been thoroughly validated yet,
they have been correlated with the VAS arm pain
(p=0.002) and VAS neck pain (p<0.0005). There is also a
correlation between Odom’s criteria and two QoL assess-
ments for spinal disorders: the Million VAS (p<0.0005)
and the Oswestry Disability Index (p<0.0005).25
In the original article, Odom’s criteria are deﬁned dif-
ferently for each item. Therefore, we modiﬁed Odom’s
criteria in analogue terms. The investigator will categor-
ise the participant, with regard to his or her symptoms
and neurological status. We will consider the ﬁrst and
second categories (‘excellent’ and ‘good’) as a success-
ful outcome of the operation.
Modified Odom’s criteria
1. Excellent: no symptoms referable to cervical disease.
Able to perform daily activities without limitations.
2. Good: moderate symptoms referable to cervical
disease. Able to perform daily activities without sig-
niﬁcant limitations.
3. Satisfactory: slight improvement of symptoms refer-
able to cervical disease. Signiﬁcant limitations in
daily activities.
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4. Poor: no improvement or aggravation of symptoms
referable to cervical disease. Not able to perform
daily activities.
Secondary outcomes:
QoL will be assessed with the EuroQol 5 Dimensions 5
level Survey (EQ-5D-5L). This survey ranks the QoL over
ﬁve dimensions in a ﬁve-level rating scale. The scores
can be converted in quality-adjusted life years (QALYs).
An improvement of 0.24 QALY will be considered clinic-
ally relevant.22
For neck disability, the Neck Disability Index (NDI)
will be used. This questionnaire consists of 10 items,
which can be ranked from 0 to 5. The sum of these
scores can be doubled to get a percentage. An improve-
ment of 17.3% will be considered clinically relevant.22
Work ability will be assessed with the single-item Work
Ability Index (WAI).26 A participant rates his or her
current ability to work, as opposed to the lifetime best
ability, on a scale from 1 to 10.
The EQ-5D-5L, NDI and single-item WAI have been
tested on their validity and reliability.26–28 Validated
Dutch language versions are used.29–31 Neck pain is
assessed with a horizontal 0–100 mm VAS.28 During the
study, we will record the types of complications and their
rates.
Cost-effectiveness and the budget impact analysis
(BIA) are calculated by means of questionnaires for
medical consumption and productivity costs. The
National Health Care Institute of the Netherlands men-
tions these questionnaires as the preferred measurement
tools for calculating economic evaluations.32
The questionnaires will be provided to the participant
in a secure online environment. If a participant does
not have access to the internet, paper questionnaires will
be sent.
Withdrawal of individual participants
Participants can discontinue the participation of the
study at any time for any reason. The investigator can
decide to withdraw a participant from the study for
urgent medical reasons (not related to the treatments
under investigation).
The aim is to include 308 participants within 2 years.
When a participant withdraws from the study, he or she
will not be replaced since a 10% loss of inclusion is
accounted for within the power calculations of the trial.
If participants withdraw after they have received the
operative treatment, their permission will be asked to
use the information from their medical ﬁles. Data of
participants after withdrawal will be used and analysed
with the intention-to-treat principle. A per-protocol ana-
lysis will be performed as well.
Data management
Data will be recorded in a web-based data capture system
(OpenClinica), which is hosted by the Trial
Coordination Center of the University Medical Center
Groningen. This system is customised and has an audit
trail facility. Ranges and programmed validation checks
are implemented in the system in order to aid reliable
data entry.
Statistical methods
Primary study parameters
The primary end point (postoperative decrease of self-
reported arm pain (VAS)) will be deﬁned as ‘operative
success’. As a second primary end point, Odom’s criteria
will be assessed. Odom’s criteria will be deﬁned as
‘patient success’. Both items will be analysed as appropri-
ate depending on data distribution with a one-sided 0.05
level of signiﬁcance (non-inferiority). We consider the
FOR technique to be non-inferior if the technique has
at least as much efﬁcacy (decrease in VAS arm pain and
the good/excellent scores on Odom’s criteria) as the
ACDF technique or is worse by an amount <10%.
Detailed descriptive statistics will be provided for the
data collected and 95% CIs will be calculated for all rele-
vant estimates. Clinical follow-up data will be analysed by
analysis of covariance or generalised model alternatives
for categorical or semiquantitative data. Changes within
the treatment groups over time, as well as differences
between groups, will be assessed by intention-to-treat
analyses. Also, the primary analysis will follow the per-
protocol principle. Sensitivity analysis will be provided to
evaluate robustness of the results with regard to unex-
pected circumstances, for example, the impact of ‘cross-
over’ and centre-related effects.
Secondary study parameters
Secondary end points will be analysed in an exploratory
manner at a two-sided signiﬁcance level of 5%. Safety
and tolerability parameters will be analysed descriptively.
Analysis of time-dependent probabilities of critical
events will be performed using the Kaplan-Meier
method. Furthermore, multivariate event analyses will be
performed using Cox proportional hazard regression
models. In addition, for the purpose of a supportive sen-
sitivity analysis, multiple imputation procedures will be
applied.
The cost-effectiveness analysis will be performed
alongside the clinical trial to assess the cost-effectiveness
of FOR versus ACDF. There will be two separate
outcome measures for the cost-effectiveness analysis,
resulting in two incremental cost-effectiveness ratios for
FOR as compared with ACDF. The ﬁrst is incremental
costs per extra percentage of patients with arm pain
relief, while the second is incremental costs per QALY
gained. EQ-5D-5L scores will be converted into health
state utilities using the Dutch value set.33 These health
state utilities range between −0.446 and 1, with a higher
utility indicating a better health-related QoL. The util-
ities will be multiplied by follow-up time spent in that
particular health state (area under the curve) to eventu-
ally convert into QALYs.
The analysis will be performed taking a societal per-
spective. The time horizon will be equivalent to the full
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follow-up of the clinical study, which is 24 months.
According to pharmacoeconomic guidelines, discount-
ing will be applied for costs (4%) and effects (1.5%) in
the second year.32 A number of sensitivity analyses will
be performed to identify the impact of variables, such as
the costs of the FOR and ACDF procedures, resource
use and effect size, on cost-effectiveness. A cost-
effectiveness acceptability curve will be constructed,
based on bootstrap simulations, showing the probability
of FOR being cost-effective compared with ACDF at
varying levels of the willingness to pay, for either one
additional percentage of patients with arm pain relief or
one additional QALY.
Based on the results of the clinical study and the cost-
effectiveness analysis, a BIA will be performed to inform
decision makers on the ﬁnancial consequences of imple-
menting FOR as treatment of ﬁrst choice for cervical for-
aminal soft disc/osteophytic disease in the Dutch
healthcare system. The BIA will be performed according
to the principles of the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR)
task force and from the perspective of the government
as well as a third party payer’s/healthcare insurer’s per-
spective.34 The trial results will be extrapolated, by
means of a simple model, from a time horizon of
24 months to 5 years, and for the entire Dutch popula-
tion concerned. The extrapolation will assume a con-
stant incidence of cervical foraminal soft disc/
osteophytic disease. We expect that the proportion of
cases eligible for surgical intervention will be stable over
time as well. Therefore, the extrapolation will be linear.
Sensitivity analyses will be performed on relevant para-
meters such as the eventual substitution rate of FOR
versus ACDF (may not be 100%), the uptake of FOR
with time, costs of the procedures and other cost items.
We will assume that current usual care already consists
of a mix of ACDF and FOR, that is, 90% and 10%,
respectively.
Monitoring
The study will be monitored by the Trial Coordination
Center of the University Medical Center Groningen.
This independent institute will examine the execution
of the study procedures and verify source data by
random sampling in the seven participating medical
centres. At least one monitoring visit per year per centre
will be conducted. All protocol deviations will be docu-
mented. The exact details of the monitoring will be
documented in a monitoring plan in accordance with
the guidelines for a low-risk to moderate-risk study.
The investigational treatments are widely accepted and
frequently performed surgical procedures by neurosur-
geons and orthopaedic surgeons. Participating in the
study does not cause any additional risk to the partici-
pant. Therefore, the investigators decided to not establish
a data monitoring committee. In the Netherlands, liability
insurance is available for all participants as insurance is
mandatory in the conduction of clinical trials.
During the complete period of the study, all adverse
events will be reported. Adverse events are deﬁned as any
undesirable experience occurring to a participant during
the study, whether or not considered related to interven-
tion. The events that will be assessed are listed in box 1.
The deﬁnition of serious adverse events is in line with
the guidelines of the International Council on
Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH):35
‘Every adverse event will be categorised as serious if it:
▸ Results in death;
▸ Is life threatening (at the time of the event);
▸ Requires hospitalisation or prolongation of existing
inpatients’ hospitalisation;
▸ Results in persistent or signiﬁcant disability or
incapacity;
▸ Is a congenital anomaly or birth defect;
▸ Concerns any other important medical event that
may not result in death, be life threatening or require
hospitalisation may be considered a serious adverse
experience when, based on appropriate medical
judgement, the event may jeopardise the participant
or may require an intervention to prevent one of the
outcomes listed above’.
If a serious adverse event occurs, the local investigator
is obliged to give direct notice (<24 hours) to the
sponsor. According to the Medical Research Involving
Human Subjects Act, the sponsor has to report the
event in 7–15 days to the reviewing committee.
ETHICS
This study will be conducted in accordance with the
Declaration of Helsinki and in compliance with the
Medical Research Involving Human Subjects Act.
Box 1 List of adverse events for the FACET study
▸ Death
▸ Thrombosis
▸ Pulmonary embolism
▸ Urinary retention
▸ Postoperative bleeding/haematoma
▸ Postoperative wound infection
▸ Nerve root injury
▸ Dural tear
▸ Postoperative cerebrospinal fluid leakage
▸ Implant malposition
▸ Vascular injury
▸ Horner’s syndrome
▸ Blood loss from the wound
▸ Urinary infection
▸ Spinal cord injury
▸ Oesophagus injury
▸ Hoarseness
▸ Pneumonia
▸ Reoperation at the index level
▸ Reoperation at adjacent level(s)
▸ Other
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Ethical approval has been granted from the
Institutional Ethics Committee of the initiating medical
centre on 5 November 2015.
Consent
A participant’s information folder in adjusted linguistics
is offered to all participants containing information
about the study aims, procedures and the risks of both
surgical techniques. In a conversation with the attending
physician, questions regarding the study will be
answered. If the patient is fully informed and willing to
participate, the informed consent form is signed. The
patient is provided with ample time to consider his or
her decision and to ask for additional information. No
maximum amount of days is set; patients can consider
their decision until the surgical treatment is scheduled.
Confidentiality
The data of the participant will be recorded and ana-
lysed without any personal identiﬁers, by using coded
information. The source documents and identiﬁcation
lists will be archived in a secured facility per centre.
Permission for accessing data will be documented per
investigator.
Dissemination
Results of this study will be disseminated through
national and international papers. The participants and
relevant patient support groups will be informed about
the results of the study.
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